Intervention Maps · Chronic low back pain · PRP / intradiscal injections
PRP and stem-cell-type intradiscal injections for low back pain
This page is about intradiscal injections such as PRP and stem-cell-type products. These are often marketed as “regenerative” treatments. The evidence has not established that they rebuild discs.
Bottom line
PRP and stem-cell-type intradiscal injections remain an investigated market. They are often sold as regenerative care. Disc repair is not established. Later trial evidence shows at most modest, mixed symptom and function signals. There is insufficient evidence that these therapies regenerate discs, and pain or function change is not the same as structural repair.
What it is
Biologic material injected into a disc, usually under imaging guidance. Products differ: platelet-rich plasma, mesenchymal stem-cell-type products, and related preparations are not interchangeable.
What taking part usually involves
A procedure visit, cost that is often out of pocket, and follow-up focused on symptoms. Marketing language can sound like structural repair. The procedure is intended to deliver material into the disc; receiving the injection does not establish that the disc will regenerate.
What this is commonly confused with
Proven disc regeneration. An epidural steroid injection. Radiofrequency denervation. Knee osteoarthritis PRP evidence treated as if it settles the spine question.
What the evidence shows
NICE does not offer spinal injections for managing low back pain.
Older reviews combine heterogeneous studies and do not provide a clear answer. Later trial reviews show at most modest, mixed symptom and function signals across products. One RCT-only review of stem-cell-type treatments found an average pain difference of about 7 points on a 100-point scale, while saline-controlled PRP results have been mixed.
There is insufficient evidence that these therapies regenerate discs. That is not the same as proof they cannot. Pain or function change is not structural repair.
Who was studied, expectations, and limits
Population and context studied: people offered intradiscal biologic injections for discogenic or degenerative disc pain claims in trials and clinics.
That is the market and research conversation, not a personal go-ahead.
Realistic expectation: possible modest symptom signals at best; no established disc rebuild. Limits: products differ a lot from one another.
Evidence consulted Open sources
Key sources used to prepare this answer. This is not a citation for every sentence.
- NICE NG59. Low back pain and sciatica in over 16s
- Schol et al. Cell transplantation and platelet-rich plasma therapy for disc degeneration-related pain (JOR Spine, 2024) · mixed-design review
- Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials (Asian Spine Journal)
- Platelet-rich plasma and stem cell therapies for spondylosis: a systematic review of randomized controlled trials (European Spine Journal, 2026)
← Back to Chronic low back pain · find this again later from “What are you trying to figure out?”